A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC).

被引：0
|
作者：
Amato, R. J. [1 ]
Misellati, A. [1 ]
Khan, M. [1 ]
Chiang, S. [1 ]
机构：
[1] Methodist Hosp Res Inst, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：224S / 224S
页数：1
相关论文
共 50 条
  • [1] A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    Amato, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] A phase II trial of RAD001 in patients (PTS) with metastatic renal cell carcinoma (MRCC)
    Amato, R.
    Jac, J.
    Giessinger, S.
    Khan, M.
    Willis, J.
    Chiang, S.
    [J]. CANCER INVESTIGATION, 2007, 25 : 20 - 21
  • [3] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Phase II trial of RAD001 in renal cell carcinoma patients with non-clear cell histology.
    Koh, Youngil
    Kim, Ji Yeon
    Lim, Ho Yeong
    Ahn, Jin-Hee
    Lee, Jae-Lyun
    Rha, Sun Young
    Kim, YuJung
    Kim, Tae Min
    Lee, Se-Hoon
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Prediction of response to RAD001 (everolimus) in patients with metastatic renal cell carcinoma
    Seidel, C.
    Fenner, M.
    Merseburger, A.
    Heuser, M.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Prediction of response to RAD001 (Everolimus) in patients with metastatic renal cell carcinoma
    Seidel, C.
    Fenner, M.
    Merseburger, A.
    Heuser, M.
    Ganser, A.
    Gruenwald, V.
    [J]. ONKOLOGIE, 2010, 33 : 105 - 105
  • [7] RAD001 and zoledronic acid in renal cell carcinoma patients with bone metastases (RAZOR): A randomized phase II trial
    Broom, Reuben James
    Hinder, Vicky
    Sharples, Katrina
    Proctor, Janie
    Duffey, Steven
    Pollard, Stephanie
    Fong, Peter C. C.
    Forgeson, Garry
    Harris, Dean Laurence
    Jameson, Michael B.
    O'Donnell, Anne
    North, Richard T.
    Deva, Sanjeev
    Hanning, Fritha J.
    Grey, Andrew
    Findlay, Michael P. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): A randomized phase II trial
    Broom, Reuben James
    Hinder, Vicky
    Sharples, Katrina
    Proctor, Janie
    Duffey, Steven
    Pollard, Stephanie
    Fong, Peter C. C.
    Forgeson, Garry
    O'Donnell, Anne
    Harris, Dean Laurence
    Deva, Sanjeev
    Jameson, Michael B.
    North, Richard T.
    Grey, Andrew
    Findlay, Michael P. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [9] RAD001 AND ZOLEDRONIC ACID IN RENAL CELL CARCINOMA PATIENTS WITH BONE METASTASES (RAZOR) - A RANDOMIZED PHASE II TRIAL
    Broom, R. J.
    Hinder, V.
    Sharples, K.
    Proctor, J.
    Duffey, S.
    Pollard, S.
    Fong, P. C. C.
    Forgeson, G.
    Harris, D. L.
    Jameson, M. B.
    O'Donnell, A.
    North, R. T.
    Deva, S.
    Hanning, F. J.
    Grey, A.
    Findlay, M. P. N.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 : 24 - 24
  • [10] A phase I study of sorafenib and RAD001 for metastatic clear cell renal cell carcinoma
    Harzstark, A. L.
    Rosenberg, J. E.
    Weinberg, V. K.
    Sun, J.
    Ryan, C. J.
    Lin, A. M.
    Fong, L.
    Brocks, D. R.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345